The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review

Megan F Patterson1
Larry Borish2,3
Joshua L Kennedy1,4

1Department of Pediatrics, Arkansas Children’s Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Department of Medicine, Carter Immunology Center, University of Virginia Health Systems, Charlottesville, VA, USA; 3Department of Microbiology, Carter Immunology Center, University of Virginia Health Systems, Charlottesville, VA, USA; 4Department of Internal Medicine, Arkansas Children’s Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Abstract: Asthma is a heterogeneous syndrome that might be better described as a constellation of phenotypes or endotypes, each with distinct cellular and molecular mechanisms, rather than as a singular disease. One of these phenotypes is eosinophilic asthma. As the development of eosinophilic inflammation is categorically dependent on the biological activity of Interleukin (IL)-5, IL-5 antagonism became an obvious target for therapy in this phenotype. Early trials of monoclonal antibodies targeting the biological activity of IL-5, including reslizumab, mepolizumab, and benralizumab, were performed on asthmatics with no concern for evidence of eosinophilia. These trials were largely unsuccessful. However, during these trials, researchers recognized the need to quantify eosinophilia in asthma subjects in order to identify those asthmatics in whom these medications would be more likely to improve symptoms and lung function. Using biomarkers, such as sputum and blood eosinophilia, recent studies of these medications have shown improvements in blood and sputum eosinophilia, forced expiratory volume in 1 second, and quality of life assessments as well as reducing occurrences of exacerbations. Moving forward, better and less invasive biomarkers of eosinophilia are necessary to ensure that the correct patients are chosen to receive these medications to receive maximal benefit.

Keywords: eosinophilic asthma, reslizumab, mepolizumab, benralizumab, IL-5, eosinophils

Introduction

Asthma is a chronic disease with a prevalence of up to ~12% of the United States population, characterized by reversible airflow obstruction, inflammation, and airway hyperresponsiveness.1–3 This disease has many presentations, ranging from mild, intermittent disease to severe, debilitating, even life-threatening symptoms requiring multiple medications, hospitalizations, and extensive health care utilization.2 For that subset, there is a need to develop treatments that prevent symptoms and improve patient morbidity and long-term management.

Despite its singular name, the term, “asthma”, actually encompasses a range of symptoms and diseases caused by distinct cellular mechanisms.4 While current guidelines classify this heterogeneous disease based on lung function, symptoms, and frequency of rescue bronchodilator use,5 efforts have been made to properly delineate asthma as distinct phenotypes. One such characterized phenotype is eosinophilic asthma, defined by the presence of eosinophils in the lungs.6 A subgroup of these patients maintains persistent eosinophilia in the airways and sputum even with conventional asthma therapy – termed steroid-resistant eosinophilic asthma.6,7 Many of these patients with eosinophilic asthma suffer significant morbidity and loss of quality
Eosinophils, IL-5, and asthma

Eosinophils comprise 1%–6% of the white blood cells and are important mediators of the allergic inflammatory response, and they are significant players in the pathogenesis and severity of chronic inflammatory disorders of the airway including asthma. In fact, tissue eosinophilia is present in 40%–60% of patients with asthma, and blood and sputum eosinophilia parallel severity of disease for those with eosinophilic asthma. Eosinophils aid in the innate immune response triggered in the airway by environmental allergens, viral infections, and other extraneous stimuli, and activation of these cells can lead to tissue damage and remodeling. Through a battery of powerful proinflammatory mediators released from tissue eosinophils, including granule-derived basic proteins, lipid mediators, cytokines, and chemokines, these cells are responsible for inflammation of the airways, leading to hyperresponsiveness in addition to airway remodeling via fibrosis, angiogenesis, and thickening of airway walls (Figure 1). Conventional therapies with inhaled corticosteroids typically reduce total amounts of eosinophils in the airways of asthmatics. However, ~50% of severe asthmatics, a group that constitutes 5%–10% of all asthma patients, have exacerbations and symptoms with persistent eosinophils in the airway despite taking high dose inhaled corticosteroids.

IL-5 is the only known human eosinophilopoietin. As such, it plays an important role in allergic inflammation via the production, maturation, recruitment, differentiation, survival, and activation of eosinophils (Figure 1). In human ex vivo studies, exposure of peripheral blood eosinophils to IL-5 can prompt their activation leading to release of toxic granules. In mouse models, overexpression of IL-5 causes eosinophilic airway inflammation and airway hyperresponsiveness. Furthermore, blocking IL-5 in these mouse models leads to diminished eosinophilia and overall inflammation. In human disease, there is a correlation in the amount of IL-5 protein and mRNA expression isolated from bronchial mucosa and bronchoalveolar lavage fluid and evidence of asthma control. Taken together, these studies suggest that blocking IL-5 with a monoclonal antibody would diminish lung tissue eosinophilia and improve asthma severity. We have summarized the clinical trials for monoclonal IL-5 antibodies in Table 1.

The history of mepolizumab: back to the drawing board

Given the relationship of IL-5 to eosinophilia and asthma severity, targeting IL-5 became an obvious choice for treatment of severe asthma (Figure 1). Studies of IL-5 knockout

---

**Figure 1:** Eosinophil (eos) trafficking and maturation in asthma.

**Notes:** Stimulation at the epithelial cell surface leads to the generation of cytokines and chemokines that increase production of IL-5. Generation of IL-5 by Th2 cells, ILC2, and mast cells is essential in eosinophil survival and activation in peripheral tissue. This figure also shows the mechanisms of action for mepolizumab, reslizumab, and benralizumab, as well as the secretory products of eosinophils. Red arrows represent inhibitory pathways, while blue arrows are activating pathways.

**Abbreviations:** EDN, eosinophil-derived neurotoxin; ECP, eosinophil cationic protein; EPO, eosinophil peroxidase; IL, interleukin; TGF-α/β, transforming growth factor-α/β; INF-γ, interferon gamma; RANTES, regulated upon activation, normal T cell expressed and secreted; MIP1α, macrophage inflammatory proteins-1α; PAF, platelet-activating factor; VIP, vasoactive intestinal peptide; NGF, nerve growth factor; TSLP, thymic stromal lymphopoietin; ILC2, innate lymphoid cells (type 2).
### Table 1 Pivotal studies in anti-iL-5 therapies

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study</th>
<th>Population</th>
<th>Study design</th>
<th>Dosing</th>
<th>Measured end points</th>
<th>Findings in treatment groups</th>
</tr>
</thead>
</table>
| Mepolizumab      | Leckie et al, 2000            | Male subjects with mild allergic asthma and FEV$_1$ of at least 70%        | $n=24$ sc, db, pc | Single IV dose of 2.5 or 10 mg/kg                                     | Responses to inhaled allergen challenge, sputum eosinophils, airway hyperresponsiveness to histamine, blood eosinophils | • Decreased blood eosinophils for up to 16 weeks and sputum eosinophils at 4 weeks  
• No significant effect on late asthmatic response to allergen challenge or airway hyperresponsiveness |
|                  | Flood-Page et al, 2007        | Asthmatic subjects with continued symptoms on inhaled corticosteroid therapy with and FEV$_1$ between 50% and 80% | $n=362$ mc, db, pc | Three IV doses of 250 or 750 mg per month                             | Morning peak expiratory flow, FEV$_1$, daily β$_2$-agonist use, symptom scores, exacerbation rates, quality of life measures, blood eosinophils, sputum eosinophils (subset of 37) | • Decreased blood and sputum eosinophils  
• No statistically significant changes in any of clinical end points measured |
|                  | Nair et al, 2009              | Asthmatic subjects with sputum eosinophilia $\geq 3\%$ and persistent airway symptoms despite treatment with dose inhaled corticosteroid and prednisone | $n=20$ sc, db, pc | Five IV doses of 750 mg per month                                    | Prednisone dose, sputum and blood eosinophils, symptoms, airflow limitation            | • Patients were able to reduce their prednisone dose significantly  
• Significantly fewer asthma exacerbations  
• Decreased sputum and blood eosinophils  
• Improvements in asthma control and FEV$_1$  
• Significantly fewer asthma exacerbations  
• Significant improvement in scores on AQLQ  
• Decreased sputum and blood eosinophils  
• No significant difference in symptoms, FEV$_1$, after bronchodilator use, or airway hyperresponsiveness |
|                  | Haldar et al, 2009            | Asthmatic subjects with history of severe persistent exacerbations with sputum eosinophilia $\geq 3\%$ | $n=61$ sc, db, pc | Twelve IV doses of 750 mg per month                                  | Severe exacerbations, asthma symptoms, Asthma Quality of Life Questionnaire (AQLQ), FEV$_1$, after bronchodilator use, airway hyperresponsiveness, blood and sputum eosinophils | • Significant reductions in exacerbations  
• No changes in FeNO, lung function, or symptom scores  
• Dose response for reduction in sputum eosinophils and to a lesser extent, blood eosinophils |
|                  | Pavord et al, 2012            | Asthmatic subjects with either a sputum eosinophil count $\geq 3\%$, an exhaled nitric oxide (FeNO) concentration of $\geq 50$ ppb, asthma-related peripheral blood eosinophil count of $\geq 300$ cells/µL, or prompt deterioration of asthma control after a 25% or less reduction in regular maintenance inhaled or oral corticosteroids | $n=621$ mc, db, pc | Three SubQ doses of 75, 250, or 750 mg every 4 weeks                | Exacerbations, FeNO, lung function, symptom scores, sputum, and blood eosinophils        | • Significant reductions in exacerbations  
• No changes in FeNO, lung function, or symptom scores  
• Dose response for reduction in sputum eosinophils and to a lesser extent, blood eosinophils |
|                  | Ortega et al, 2014            | Subjects with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high doses of inhaled corticosteroids | $n=576$ mc, db, pc | Nine doses of 75 mg IV or 100 mg SC every 4 weeks                   | Exacerbations, lung function, ACQ5 symptom score, blood eosinophil count, SGRQ, quality of life tool | • Reduced exacerbation rates  
• Significant improvements in lung function (FEV$_1$, ACQ5, and SGRQ)  
• Decreased blood eosinophils |

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study</th>
<th>Population</th>
<th>Study design</th>
<th>Dosing</th>
<th>Measured end points</th>
<th>Findings in treatment groups</th>
</tr>
</thead>
</table>
| Bel et al, 2014<sup>39</sup> | Subjects on systemic glucocorticoids and evidence of eosinophilic inflammation (blood eosinophil level of either $\geq 300$ cells/mL before screening or $\geq 150$ cells/mL during optimization phase) | $n=135$ mc, db, pc | Six SubQ doses of 100 mg every 4 weeks | % reduction in daily oral steroid dose, exacerbations, ACQ5 symptom scores, SGRQ quality of life score, FEV<sub>1</sub> | • 50% reduction in daily oral steroid dose  
• Significant reductions in rate of exacerbations  
• Improvement in ACQ5 scores and SGRQ scores  
• Trend for improvement in FEV<sub>1</sub> |
| Reslizumab   | Kips et al, 2003<sup>11</sup> | Subjects with severe persistent asthma, defined as those being symptomatic despite being treated with high doses of inhaled and/or oral corticosteroids | $n=28$ mc, db, pc | Single IV dose of 0.03, 0.1, 0.3, or 1 mg/kg | Sputum and blood eosinophil counts, symptom severity, lung function parameters, and physician-evaluated overall condition | • Dose dependently reduced circulating eosinophil counts  
• No significant changes in other clinical measurements of disease activity  
• Significant reduction in ACQ score in patients with nasal polyps (versus trend in entire treatment group)  
• Decreased sputum eosinophils  
• Improvements in airway function (significant reduction in FEV<sub>1</sub>)  
• Trend toward reduced exacerbations  
• Significant improvement in FEV<sub>1</sub>  
• Significant reduction in ACQ scores  
• Higher dose showed earlier FEV<sub>1</sub> increase  
• Trend toward decreased exacerbation rate in 100 mg group  
• Significant improvement in FEV<sub>1</sub> and ACQ in eosinophilic patients  
• Decreased blood eosinophils  
• High incidence of adverse reactions in treatment group |
| Castro et al, 2011<sup>10</sup> | Subjects with asthma treated with high dose inhaled corticosteroids with at least one other agent that was poorly controlled and $\geq 3$% sputum eosinophils | $n=106$ mc, db, pc | Four SubQ doses of 3 mg/kg every 4 weeks | | Change in ACQ score, FEV<sub>1</sub>, sputum eosinophils, asthma exacerbation – measured in all patients versus those with nasal polyps | |
| Bjerner et al, 2014<sup>46</sup> | Subjects with uncontrolled asthma on at least medium ICS and blood eosinophil level of $\geq 400$ µL | $n=311$ mc, db, pc | Four IV doses of 0.3–3 mg/kg every 4 weeks | Pre-dose and pre-bronchodilator pulmonary function (primarily FEV<sub>1</sub>) and ACQ scores | | |
| Benralizumab | Castro et al, 2014<sup>44</sup> | Asthmatic subjects on maximal conventional therapies with peripheral blood eosinophil counts $\geq 300$ cell/µL | $n=609$ mc, db, pc | Seven SubQ doses of 2, 20, or 100 mg for eosinophilic patients and 100 mg for non-eosinophilic | Annual exacerbation rate, FEV<sub>1</sub>, ACQ, blood eosinophils | | |

**Abbreviations:** sc, single center; mc, multicenter; db, double-blind; pc, placebo controlled; SubQ, subcutaneous; IV, intravenous; AQLQ, Asthma Quality of Life Questionnaire; ACQ, Asthma Control Questionnaire; SGRQ, St George's Respiratory Questionnaire; FEV<sub>1</sub>, forced expiratory volume in 1 second; ICS, inhaled corticosteroids.
animals were encouraging.\textsuperscript{20,22} Preliminary studies with humans further reinforced the idea of targeting of IL-5 and therefore eosinophils.\textsuperscript{10,29} However, when studies began to shift to asthma symptoms and improvement of lung function, the IL-5 antibodies were disappointing as a solution for asthmatics, who continued to suffer from persistent symptoms despite maximized standard therapy. In order to learn from this history, we present data from these early experiments as follows.

Leckie et al studied mepolizumab, a monoclonal antibody against IL-5, and its effects on eosinophils, airway hyperresponsiveness, and the late phase allergic response, a process driven by eosinophils. This group found that mepolizumab effectively reduced the blood eosinophil count and this effect was maintained up to 16 weeks after the dose. Further, this drug reduced blood eosinophils after allergen challenge and decreased sputum eosinophils. The consequence of reduced eosinophilia in these subjects was predicted to be diminished airway hyperresponsiveness and late phase allergic responses. However, there was no significant effect observed on either outcome. The results of this study cast uncertainty on the exact relationship between the late phase allergic response, airway hyperresponsiveness, and eosinophilia. Upon closer examination of the population studied, the majority were men with history of intermittent wheezing and shortness of breath, diagnosed with mild allergic asthma with a forced expiratory volume in 1 second (FEV\textsubscript{1}) of at least 70%. There were no initial evaluations performed to determine the level of eosinophilia within these subjects prior to the onset of the study.\textsuperscript{30}

In another study, Flood-Page et al studied two doses of mepolizumab versus placebo in asthmatic patients with continued symptoms on inhaled corticosteroid therapy with an FEV\textsubscript{1} between 50% and 80%. The measured end points for this study included blood and sputum eosinophils, airway hyperresponsiveness, and the late phase allergic response. As specific secondary end points, this group further evaluated change from baseline in domiciliary morning peak expiratory flow, changes from baseline FEV\textsubscript{1}, asthma summary symptom scores, use of rescue bronchodilator medications, quality of life scores, and asthma exacerbation rates. As with the study by Leckie et al, there was a significant, persistent decrease in blood and sputum eosinophils in the IL-5 monoclonal antibody groups compared to placebo. However, regardless of this observed reduction in eosinophilia, clinical effects were minimal. There were no statistically significant clinical benefits observed over the course of the study, including no apparent effect on airway hyperresponsiveness or late phase allergic responses after allergen challenge. Furthermore, there were no significant changes in FEV\textsubscript{1} between treatment groups and all three groups had decreases in mean asthma summary symptom scores. Interestingly, the greatest decrease in mean asthma summary symptom scores was seen in the placebo group and there were no significant differences seen in rescue medication use or mean Asthma Quality of Life Questionnaire (AQLQ) scores. While not significant, a trend was observed of fewer asthma exacerbations in those subjects on the higher dose treatment with mepolizumab.\textsuperscript{31}

Anti-IL-5 antibodies seemed destined to be placed on the back shelf as they did not seem to provide any clinical benefit in difficult-to-treat patients. However, these studies became the archetype of the importance of choosing the correct population and primary end points for study of particular drugs. With the advent of personalized medicine, some researchers saw an important phenotype that might respond much differently to these medications – the eosinophilic asthmatic. Equally as important for determining the utility of these medications in the appropriate population proved to be defining the correct outcome parameter(s) for the study. We will discuss these issues further in the following section.

**The history of mepolizumab: the importance of phenotype**

When anti-IL-5 therapies have been used in a patient population selected for eosinophils, results have been more promising. Nair et al evaluated mepolizumab in a group of patients selected for sputum eosinophilia (at least 3%) and persistent airway symptoms despite treatment with high dose inhaled corticosteroid and prednisone. The primary end point for this study specifically examined the steroid-sparing effect of mepolizumab. The subjects who took mepolizumab were able to reduce oral steroids with an average reduction in prednisone of 11.9 to 3.9 mg in the treatment group and a reduction from 10.7 to 6.4 mg in the placebo arm. This reduction of prednisone dose was significantly different ($P=0.04$). However, the final prednisone doses were not significantly different between groups. As in the previously mentioned studies, there was a significant reduction in eosinophils in circulation and sputum. However, unlike previous studies, in these subjects with high sputum eosinophils, improvements in asthma control were made as evidenced by improvement in scores on the Juniper Asthma Control Questionnaire (ACQ) and modest improvements in FEV\textsubscript{1} that were maintained for 8 weeks. Furthermore, in those receiving mepolizumab, the median time to exacerbation was 20 weeks as compared to 12 weeks in the placebo group ($P=0.003$). In ten placebo subjects, there were 12 exacerbations, and, at the time of
exacerbation, nine had sputum eosinophilia. In the mepolizumab group, only one subject had an asthma exacerbation. There was also improvement in symptoms; however, this was not statistically significant. These findings were counter to the previous studies that had negative results in subjects not selected for eosinophilia, drawing attention to the need to identify biomarkers that would predict response to therapy for these medications.

Further support of this idea was shown by Haldar et al. This study was performed with subjects who had a history of severe persistent exacerbations with eosinophilic asthma as evidenced by sputum eosinophilia ≥3%. In this study, the number of severe exacerbations during treatment was the primary outcome measure with other measured outcomes, including change in asthma symptoms, AQLQ, FEV\textsubscript{1} after use of bronchodilator, airway hyperresponsiveness, and number of eosinophils in the blood and sputum. As with all previous studies of anti-IL-5, blood and sputum eosinophils were significantly decreased. Over the 50-week period, patients receiving mepolizumab had significantly fewer asthma exacerbations than those in the placebo group. Per subject, there were on average 2.0 severe exacerbations in the mepolizumab group compared to 3.4 in placebo. Closer examination of hospital admissions during exacerbations revealed only three in the mepolizumab group, with eleven in the placebo group. This decrease in number of admissions was not statistically significant, though arguably was clinically significant; however, the length of hospital stay during exacerbations was significantly less for the mepolizumab group contrasted with placebo. Further, those in the mepolizumab group had significant improvement in scores on the AQLQ. The investigators also evaluated computed tomography images of the lungs to scrutinize airway wall thickness and total wall area, and these were both decreased in those receiving mepolizumab. Others have shown that mepolizumab decreases extracellular matrix protein deposition, which might explain improvements in airway wall thickness. Nonetheless, there was no significant difference in symptoms, FEV\textsubscript{1} after bronchodilator use, airway hyperresponsiveness, and rescue bronchodilator use.

The DREAM study by Pavord et al. was a multicenter, double-blind placebo-controlled trial of subjects with severe asthma. Subjects were enrolled if they had one of the following: either a sputum eosinophil count ≥3%, an exhaled nitric oxide (FeNO) concentration of ≥50 ppb, asthma-related peripheral blood eosinophil count of ≥300 cells/µL, or prompt deterioration of asthma control after a 25% or less reduction in regular maintenance inhaled or oral steroids. Subjects were provided with one of three different doses of mepolizumab or placebo. Ultimately, 616 participants completed the treatment with 13 infusions at 4-week intervals. The primary outcome of the study was the rate of clinically significant asthma exacerbations occurring in the 52 weeks of treatment and 4 weeks after completion of treatment. Clinically significant asthma exacerbations were defined as “worsening of asthma requiring the use of oral corticosteroids for 3 or more days, admission, or a visit to the emergency department”. This study again showed diminished blood and sputum eosinophils during the course of treatment for the active group. In this study, 75 mg of intravenous (IV) mepolizumab every month, the lowest dose in the study, decreased clinically significant asthma exacerbations by 48% during the course of treatment. The 250 mg and the 750 mg also improved asthma exacerbations, but with no more significant gains than that obtained by 75 mg. There are two possibilities as to why this might be the case. First, it is possible that a certain proportion of exacerbations are not eosinophil dependent, despite the fact that they are occurring in patients with high numbers of eosinophils. Alternatively, this finding may represent that mepolizumab does not completely abolish airway eosinophils. We speculate that this may be the result of IL-5-independent prolongation of survival and activation of eosinophils in the tissues by GM-CSF or IL-3. There were only small effects on FEV\textsubscript{1} and ACQ scores, which were not statistically significant. The authors postulate that day-to-day symptoms are separate from exacerbations associated with severe asthma, and they may “require different management strategies”.

In 2014, Ortega et al studied 576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high doses of inhaled corticosteroids. Subjects were randomized into one of three groups: 75 mg IV mepolizumab, 100 mg subcutaneous mepolizumab, or placebo. They found that both IV and subcutaneous mepolizumab reduced exacerbation rates (47% and 53%, respectively) compared to those receiving placebo. Severe exacerbations requiring an emergency department visit were decreased by 32% in the IV group and 61% in the subcutaneous group. Both FEV\textsubscript{1} and AQLQ scores increased for both the IV and subcutaneous mepolizumab as compared to placebo.

Finally, Bel et al studied mepolizumab with the primary outcome of its ability to spare oral corticosteroids. In this study, 135 subjects were randomized to receive either 100 mg mepolizumab subcutaneously or placebo. The mepolizumab group was able to reduce corticosteroid doses by 50% compared to no reduction in the placebo group. The treatment
group also showed a relative reduction in the rate of asthma exacerbations, underscoring the importance of eosinophils in exacerbations of asthma.  

The history of mepolizumab: the importance of choosing outcomes

In the studies mentioned earlier, the authors consistently found that mepolizumab was effective at improving rates of exacerbations in the eosinophilic asthmatic. In contrast, there were few to no consistent effects on quality of life, nor were there consistent changes in objective measures of asthma, including FEV$_1$, airway hyperreactivity, symptoms, or rescue inhaler use.  

These findings suggest that the cellular inflammatory mechanisms driving day-to-day symptoms are separate from those driving exacerbations, with exacerbations more consistently reflecting an eosinophil-driven process. Furthermore, these observations should also drive the expectations that clinicians will provide to their patients when offering these types of medications when they are approved and use them primarily targeted to patients with a history of frequent exacerbations. Finally, these studies drive the overarching point that along with choosing the right asthma phenotype, choosing the right primary outcome for clinical studies is paramount for determining the efficacy of a given intervention.

Reslizumab and asthma

Reslizumab, an IgG4/κ humanized monoclonal antibody, was also created to neutralize circulating IL-5 and prevent it from binding eosinophils (Figure 1). This particular monoclonal antibody has been studied in both United States and Europe for the treatment of moderate to severe asthma with persistent eosinophilia despite typical treatments. It is given IV every 4 weeks.  

As with mepolizumab, early clinical trials of reslizumab in the treatment of severe asthma patients with uncontrolled symptoms were not promising.  

In fact, these trials also showed no improvement in FEV$_1$ or symptoms. However, researchers did again report a significant and profound reduction in circulating eosinophils. Phase II trials emphasized evidence of eosinophils (sputum eosinophils >3%) for enrollment, and, as with mepolizumab, these studies were more successful with regards to treatment end points. The reslizumab cohort exhibited a decrease in sputum eosinophilia as well as a modest but nonsignificant improvement in asthma control by ACQ. However, this trial also recognized an important subgroup of asthmatics with nasal polyposis, which showed robust improvement of asthma symptoms ($P=0.012$).  

The association with chronic rhinosinusitis with nasal polyposis is almost certain to define a phenotype of asthmatics with disease driven by eosinophilic inflammation. However, efficacy in this cohort may also reflect the ability of IL-5 antagonism to improve chronic rhinosinusitis with nasal polyposis with secondary improvements in asthma in response to reduced sinonasal inflammation.

Phase III trials in Europe compared the efficacy of reslizumab to placebo as an add-on therapy to recommended asthma medications in subjects with moderate-to-severe persistent disease and elevated blood eosinophils (>400/µL). This study showed significantly improved FEV$_1$ and ACQ score (treatment difference vs placebo: 115 and 160 mL, FEV$_1$, and 0.238 and 0.359 ACQ, respectively).  

In another study performed in the United States, Castro et al evaluated reslizumab in subjects with elevated sputum eosinophils (>3%). The primary end point of this study was enhanced quality of life as suggested by improved ACQ scores. This group showed significant improved ACQ and FEV$_1$ in the treatment group. In a subgroup post hoc analysis, this group evaluated those subjects with nasal polyps and showed even more improvement in ACQ in this group compared to those without nasal polyps.  

In those with nasal polyposis, it was previously suggested the best predictor for nasal symptom response to reslizumab was nasal IL-5 levels.

Benralizumab and asthma

Benralizumab takes a slightly different approach to IL-5 antagonism by blocking IL-5Rα. As with the other monoclonal antibodies to IL-5, this drug significantly depletes blood and airway eosinophils. Basophils also have IL-5R on their surface and are thereby also targeted by benralizumab. As a unique mechanism of action compared to mepolizumab or reslizumab, benralizumab facilitates antibody-dependent cell-mediated cytotoxicity of both basophils and eosinophils, allowing for an active immune response to these cells rather than the passive approach of the other two medications, which primarily act to block their differentiation and survival.  

In Phase IIIB trials of subjects with severe asthma on maximal conventional therapies with peripheral blood eosinophil counts >300 cell/µL, benralizumab reduced exacerbation rates compared with placebo at both 20 and 100 mg doses. These findings again emphasize the importance of choosing the correct primary end point, one driven by eosinophilic inflammation.

Personalized medicine

Medication costs for asthma, especially for monoclonal antibodies, have skyrocketed. Phase I studies of reslizumab and
mepolizumab have made it abundantly clear that biomarkers are necessary to predict which subset of severe asthmatics will respond best to these medications. The presence of sputum and blood eosinophils have been used to identify subjects who go on to demonstrate improvements in frequency of exacerbations and to a lesser extent in quality of life and other parameters. Unfortunately, induced sputum is impractical and is almost certain not to achieve US Food and Drug Administration (FDA) endorsement as a basis for recommending use of these agents and circulating eosinophilia may have only modest value in predicting airway pathology. In this section, we will discuss alternative biomarkers that could be used to predict responses to anti-IL-5 therapies.

With the advent of easier to use and more cost-effective ways to measure expired FeNO, many practitioners are turning to this test to aid in the treatment of patients with asthma. Levels of FeNO correlate well with numbers of eosinophils in the lungs in a number of studies. In a study by Schleich et al, a FeNO >21 correlated well with having ≥3% sputum eosinophils and as such could theoretically be used as a less invasive biomarker supporting use of IL-5 antagonizing agents. These findings have been confirmed in a study by Westerhof et al. However, in a study by Wagener et al, FeNO corresponded to sputum eosinophilia in only 78% of subjects, a result also observed in the DREAM study mentioned earlier.

Serum periostin, a marker that reflects the biological activity of IL-13, has been used to predict responders to lebrikizumab (anti-IL-13 monoclonal antibody). However, there is conflicting evidence regarding its ability to distinguish eosinophilic asthma. In a study by Jia et al, serum periostin levels were the single best predictor of airway eosinophilia, even when compared to FeNO. On the other hand, both Westerhof et al and Wagener et al show that neither periostin nor total IgE were able to distinguish eosinophilic from non-eosinophilic airway inflammation. Given the conflicting information, it seems that further evidence is necessary to determine whether periostin discriminates between eosinophilic and non-eosinophilic asthma.

Nasal IL-5 levels have also been proposed to classify asthmatic subjects with regard to their likelihood of responding to anti-IL-5 therapies. As mentioned, in their study of reslizumab, Castro et al showed that the subgroup of patients with nasal polyps showed even more improvement in ACQ. Alternatively, other nasal wash markers that indirectly reflect eosinophilia might define responders to anti-IL-5 therapies, such as eosinophil-recruiting chemokines (CCL11 [eotaxin] or CCL5 [RANTES]) or eosinophil-secreted products such as EDN. However, none of these biomarkers is fully accepted as a direct marker of lung eosinophilia. The use of these approaches is further constrained by the absence of validated methodologies for either collecting samples or quantifying results.

**Conclusion**

Asthma is a heterogeneous disease, and, through time and clinical experience, it has become clear that one “size” does not fit all when it comes to therapies. Guideline-based therapies work for the majority of patients; however, there are some who continue to have symptoms despite typical recommended treatments. One specific asthma phenotype is defined by the presence of persistent eosinophilic inflammation despite high dose inhaled corticosteroids therapy, and many of these patients have multiple exacerbations each year with diminished quality of life. With the advancement of monoclonal antibodies to IL-5 and its receptor and the development of specific biomarkers that define eosinophilia, reslizumab, mepolizumab, and benralizumab are becoming viable options to aid in treatment of these patients. In fact, an FDA advisory committee has recently approved the use of mepolizumab for patients with eosinophilic severe asthma. While expensive, these antibodies have shown great promise in patients with persistent eosinophilia despite high dose inhaled corticosteroids therapy, particularly in reducing the number of exacerbations. Moving forward, it will be important to develop more specific and easier to obtain biomarkers, which will provide the best information with regard to who will respond to these therapies. Further, with the generation of several new monoclonal antibodies for use with asthma, studies need to be performed that distinguish which patients will respond to particular antibodies, both within and between classes (ie, Who will respond to mepolizumab vs benralizumab? Who will respond to mepolizumab vs lebrikizumab?) These anti-IL-5 monoclonal antibodies will very soon provide another treatment in the asthma toolbox.

**Disclosure**

Dr Megan F Patterson and Dr Larry Borish do not report any conflicts of interest in this work. Dr Joshua L Kennedy has grants to study asthma from the National Institutes of Health (KL2TR000063, UL1TR000039, P20GM103625) and the Arkansas Biosciences Institute.

**References**


